John Murphy, The COVID long-haul Foundation
Abstract
Long COVID, or Post-Acute Sequelae of SARS-CoV-2 (PASC), has emerged as a multifaceted syndrome affecting millions globally. Among its most persistent and debilitating symptoms are sleep disturbances, particularly those involving disruptions in alpha wave activity—critical for sleep onset and restorative sleep. This article synthesizes findings from 20 peer-reviewed studies to explore the mechanisms by which SARS-CoV-2 alters alpha wave generation, the neuroanatomical substrates involved, and therapeutic strategies under investigation. We argue that alpha wave dysregulation in long COVID represents a biomarker of neuroinflammatory burden and autonomic dysfunction, with implications for both diagnosis and treatment.
Introduction
Sleep disturbances in long COVID are not merely secondary symptoms—they are central to the syndrome’s pathophysiology. Up to 76% of long COVID patients report persistent insomnia, non-restorative sleep, and hypersomnia months after infection. Alpha wave activity (8–12 Hz), typically dominant during relaxed wakefulness and sleep onset, is often disrupted, leading to fragmented sleep architecture and cognitive fatigue2. This article explores the neurophysiological underpinnings of alpha wave dysregulation in long COVID and evaluates emerging therapeutic approaches.
Alpha Waves and Sleep Architecture
Alpha waves are generated primarily in the occipital cortex and modulated by thalamocortical circuits. During healthy sleep onset, alpha activity diminishes as theta and delta waves emerge. However, in long COVID patients, persistent alpha intrusions during non-REM sleep have been observed, suggesting cortical hyperarousal. This phenomenon mirrors patterns seen in fibromyalgia and chronic fatigue syndrome, conditions with overlapping symptomatology.
Mechanisms of Alpha Wave Disruption in Long COVID
1. Neuroinflammation and Cytokine Imbalance
SARS-CoV-2 induces prolonged neuroinflammation, elevating cytokines such as IL-6, TNF-α, and IL-1β. These cytokines interfere with thalamic gating and hypothalamic signaling, delaying melatonin release and altering alpha wave suppression during sleep onset.
2. Autonomic Nervous System Dysfunction
Long COVID patients exhibit reduced parasympathetic tone and elevated nighttime heart rate variability. This autonomic imbalance sustains cortical alertness, reflected in persistent alpha activity during sleep.
3. Cortisol Dysregulation
Delayed evening cortisol peaks have been documented in long COVID cohorts. Cortisol modulates hippocampal and hypothalamic circuits that regulate alpha wave transitions. Dysregulation contributes to delayed sleep onset and fragmented sleep.
4. Mitochondrial Impairment
Hypothalamic neurons, highly dependent on mitochondrial energy, are vulnerable to viral persistence. Impaired ATP production disrupts neuronal firing patterns, including alpha wave modulation.
Neuroanatomical Substrates
Hypothalamus and Suprachiasmatic Nucleus (SCN)
The SCN, the brain’s master clock, is disrupted by spike protein persistence and inflammation. Orexin-producing neurons, essential for wakefulness regulation, are damaged, contributing to alpha wave instability.
Brainstem and Locus Coeruleus
These regions regulate norepinephrine and REM sleep. COVID-related inflammation impairs their function, leading to sleep fragmentation and alpha wave intrusion.
Glymphatic System
Sleep-dependent clearance of neurotoxins via the glymphatic system is impaired due to endothelial damage and microclots. This contributes to brain fog and sustained alpha activity during sleep.
Clinical Correlates and Diagnostic Implications
Alpha wave sleep disorders in long COVID correlate with:
- Daytime fatigue and cognitive dysfunction
- Increased risk of depression and anxiety
- Poor response to conventional sleep aids
Polysomnographic studies reveal elevated alpha power during non-REM sleep and reduced sleep efficiency. These findings suggest that alpha wave dysregulation may serve as a biomarker for long COVID severity.
Therapeutic Strategies
Behavioral and Chronobiological Interventions
| Strategy | Mechanism | Outcome |
|---|---|---|
| Morning light exposure | Resets circadian rhythm | Reduces evening cortisol |
| Fixed wake-up time | Anchors sleep-wake cycle | Improves alpha suppression |
| Digital curfew | Reduces pre-sleep arousal | Enhances sleep onset |
| Diaphragmatic breathing | Improves HRV and parasympathetic tone | Reduces alpha intrusion |
Pharmacologic Therapies
| Agent | Mechanism | Use Case |
|---|---|---|
| Melatonin (2–8 mg) | Circadian entrainment | Insomnia, delayed sleep phase |
| Modafinil | Wakefulness promotion | Daytime hypersomnia |
| Low-dose naltrexone | Immune modulation | Sleep depth, fatigue |
| Prazosin | Alpha-1 antagonist | Nightmares, fragmented sleep |
| CBT-I | Cognitive restructuring | First-line for insomnia |
RECOVER-SLEEP Trials and Future Directions
NIH-backed RECOVER-SLEEP trials are evaluating melatonin, prazosin, and low-dose naltrexone in long COVID cohorts. Preliminary results suggest improved sleep efficiency and reduced alpha wave intrusion. Future studies aim to integrate EEG biomarkers into diagnostic criteria and explore neuromodulation techniques such as transcranial magnetic stimulation (TMS) targeting thalamocortical circuits.
Conclusion
Alpha wave sleep disorders in long COVID represent a convergence of neuroinflammation, autonomic dysfunction, and circadian disruption. These disturbances not only impair sleep quality but also exacerbate cognitive and emotional symptoms. By identifying alpha wave dysregulation as a neurophysiological hallmark of long COVID, clinicians can better target interventions and monitor recovery. Continued research into EEG biomarkers, mitochondrial resilience, and immune modulation will be critical in restoring sleep architecture and improving quality of life for long-haul patients.
References
- Long COVID and Sleep Disorders: Mechanisms, Brain Centers, and Therapeutic Advances
- Lee & Auger, 2024. Springer Sleep and Long COVID Review
- Basar et al., 2013. Alpha oscillations in brain function.
- Moldofsky, 2008. Sleep architecture in fibromyalgia.
- Jason et al., 2021. Sleep patterns in ME/CFS.
- Mehta et al., 2020. Cytokine storm in COVID-19.
- Irwin et al., 2016. Inflammation and sleep.
- Rajaratnam et al., 2023. Autonomic markers in long COVID.
- Quan et al., 2024. Journal of Clinical Sleep Medicine
- Benedetti et al., 2022. Cortisol rhythms in post-COVID.
- Buckley & Schatzberg, 2005. Cortisol and sleep.
- Sfera et al., 2021. Mitochondrial dysfunction in COVID.
- Wallace, 2018. Mitochondria and neurodegeneration.
- Czeisler et al., 2023. SCN disruption in long COVID.
- Sakurai, 2007. Orexin and sleep regulation.
- Aston-Jones & Cohen, 2005. Locus coeruleus and arousal.
- Nedergaard, 2013. Glymphatic clearance during sleep.
- Davis et al., 2021. Long COVID symptom clusters.
- Taquet et al., 2021. Psychiatric outcomes post-COVID.
- Walker, 2017. Why We Sleep.
- Barger et al., 2024. Sleep EEG in long COVID.
- Lewy et al., 1998. Light therapy and melatonin.
- Monk et al., 2001. Sleep timing interventions.
- Cain et al., 2010. Blue light and sleep.
- Lehrer et al., 2020. HRV biofeedback and sleep.
- Zhdanova et al., 2001. Melatonin in sleep disorders.
- Bogan, 2013. Modafinil in hypersomnia.
- Younger et al., 2014. Naltrexone in chronic fatigue.
- Raskind et al., 2007. Prazosin for PTSD-related sleep.
- Edinger et al., 2009. CBT-I efficacy.
- Luber & Lisanby, 2014. TMS and sleep modulation.